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A b s t r A c t
Elevated low-density lipoprotein cholesterol (LDL-C) has traditionally been con-
sidered as an independent risk factor for coronary artery disease (CAD). A level of 
LDL-C< 70 mg/dl is recommended for very high risk individuals. However, it has 
recently been suggested that the threshold for atherosclerosis may be much lower and 
it is widely accepted that even with the intense use of statins, not all cardiovascular 
adverse events are prevented. Consequently, new indexes have emerged that could 
outperform LDL-C especially in the highest risk populations, such as patients with 
diabetes type II or the metabolic syndrome. Non- HDL cholesterol is defined as all 
of the cholesterol that is not HDL (total cholesterol- HDL cholesterol). It has been 
shown that for each LDL-C category, according to NCEP- Adult Treatment Panel III, 
an increase in non-HDL cholesterol increased the risk for cardiovascular disease. It 
seems that the combination of a high concentration of triglyceride- rich particles and 
LDL-C carries a particularly high risk and increasing VLDL and IDL concentrations 
add to the risk at any LDL concentration. Total apo-B level reflects the total number 
of apo- B lipoproteins and measures the total atherogenic particle number. It seems 
that apo-B levels are much more closely related to the risk of vascular events than 
LDL-C or non-HDL cholesterol as presented in many large prospective trials. There 
are at least seven distinct subclasses of LDL of different particle sizes and several 
recent studies have suggested that LDL subfraction distribution, especially the pres-
ence of increased levels of small, dense LDL particles, aid in the prediction of cardiac 
heart disease risk. Further studies will clarify the clinical circumstances that justify 
lipoprotein analysis and how to best use the information taken from new indices such 
as non-HDL, apolipoprotein B or small dense LDL particles, in the management of 
our patients.
Cardiovascular disease is the leading cause of death in the developed countries 
and in a few decades it will become the leading cause of death in the developing world 
as well1. Therefore, the early identification of individuals at increased risk is of pivotal 
importance in order to modify the factors contributing to this high risk profile.
Elevated low-density lipoprotein (LDL) cholesterol has traditionally been consid-
ered as an independent risk factor for coronary artery disease (CAD). A number of 
trials have suggested that lowering LDL-cholesterol leads to a decrease in the incidence 
of CAD2-5. Moreover recent randomized statin trials have found progressively lower 
risk with progressively lower LDL-C levels6,7. The National Cholesterol Education 
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Program (NCEP) Adult Treatment Panel (ATP) endorses 
LDL-C as the basis for risk stratification and treatment goal8. 
A level of LDL-C< 70 mg/dl is recommended for very high 
risk individuals. However, it has recently been suggested that 
the threshold for atherosclerosis may be much lower3 and it is 
widely accepted that even with the intense use of statins in or-
der to achieve the aforementioned goals, not all cardiovascular 
adverse events are prevented. Consequently, researchers are 
trying to identify new indexes that would outperform LDL-
C especially in the highest risk populations such as patients 
with diabetes type II or the metabolic syndrome. Therefore, 
the role of non-HDL cholesterol, apolipoprotein B levels 
and small dense LDL particles as independent predictors of 
cardiovascular disease is currently under evaluation.
N O N -  H D L  c H O L E s t E r O L 
Non-HDL cholesterol is defined as all of the cholesterol 
that is not HDL (total cholesterol- HDL cholesterol) and 
comprises the cholesterol concentration of all the apoB- li-
poproteins, i.e. VLDL, LDL, IDL and lipoprotein(a) . If the 
triglyceride level is more than 200 mg/dl, the increase of non- 
HDL cholesterol reflects the increase of triglyceride rich lipo-
proteins i.e. VLDL. Recent data suggest that non-HDL-C is a 
good predictor of initial CAD and independent of  the levels of 
LDL11. Conducting analysis of the Framingham database, Liu 
et al. demonstrated that the risk for CAD associated with high 
non-HDL cholesterol was independent of LDL- C concentra-
tion. Moreover, for each LDL-C category, according to NCEP- 
ATP III, an increase in non-HDL cholesterol increased the 
risk. It seems that the combination of a high concentration of 
triglyceride- rich particles and LDL-C carries a particularly 
high risk and increasing VLDL and IDL concentrations add 
to the risk at any LDL concentration. Moreover, non-HDL-C 
has been associated with recurrent episodes of angina pectoris 
and nonfatal myocardial infarction in patients with multives-
sel CAD12. Data from the Lipid Research Clinic Program 
cohort study13 were used to compare the predictive value of 
non-HDL-C as a risk factor for cardiovascular  mortality with 
LDL-C. The follow-up period was 1 years. In men as well 
as in women, an increase in non-HDL-C level was associated 
with an increase in cardiovascular mortality and the relative 
risk was 2.14 in men with non-HDL-C >220 mg/dl compared 
to those with non-HDL-C < 160 mg/dl. In patients with hyper-
triglyceridemia or the metabolic syndrome, the NCEP- ATP 
III introduced non-HDL-C as a treatment target and many 
authors have supported the suggestion to estimate non-HDL C 
when assessing the risk in patients with low to normal LDL- C 
and treating targets are calculated by adding 30 mg/dl to the 
standard NCEP-ATP III target LDL-C.
A P O L I P O P r O t E I N  b
Each one of the atherogenic lipoproteins, i.e. each chy-
lomicron, VLDL, IDL, LDL, and lipoprotein(a) contain only 
1 molecule of apo-B. Therefore, the total apo-B level reflects 
the total number of apo- B lipoproteins and measures the 
total atherogenic particle number. Thus, in a patient with 
normal LDL-C, high apo-B levels may reflect higher number 
of small, dense, highly atherogenic LDL particles. Apo-B 
binds the atherogenic lipoproteins to proteoglycans on the 
arterial wall, thus facilitating the integration of cholesterol in 
the macrophages of the subendothelial space which transform 
into foam cells. Moreover, the oxidation of apo-B creates 
proinflammatory products that propagate atherosclerosis in 
the arterial wall14. Apo-B is more closely related to inflamma-
tory markers than total cholesterol, LDL-C or non-HDL-C15. 
This relation was superior to many other risk factors including 
body mass index, abdominal obesity, systolic blood pressure, 
fasting glucose, etc. Finally, the value of apo-B levels in the 
prediction of metabolic syndrome and diabetes, particularly 
in women has been shown16. It seems that apo-B levels are 
much more closely related to the risk of vascular events than 
LDL-C or non-HDL-C as presented in many large prospective 
trials such as the AMORIS17 study, the Health Professionals 
Follow-up Study18 and the Quebec Cardiovascular Study1.  In 
the latter study, non-HDL-C was strongly correlated with apo-
B across all cardiac heart disease categories (r=0.) and this 
correlation was much stronger than the correlation between 
LDL-C and apo-B, which became weaker with increasing 
triglyceride levels. Moreover, this study showed that in patients 
with CAD, both non-HDL cholesterol and apo-B levels were 
significantly elevated compared to LDL- C, so greater reduc-
tion in non- HDL cholesterol and apo-B than LDL-C would 
be required for optimal risk management. Finally, apo-B 
appears to be a better predictor of subsequent CAD events 
in patients on treatment with statins20. However, despite the 
clinical importance of apo-B levels, the cost and difficulties in 
the measurement due to lack of standardization across centers 
precludes its widespread clinical use.
s m A L L  D E N s E  L O W - D E N s I t Y  
L I P O P r O t E I N
There are at least seven distinct subclasses of LDL of dif-
ferent particle sizes. Several recent studies have suggested that 
LDL subfraction distribution aids in the prediction of cardiac 
heart disease risk. The Quebec Cardiovascular Study1 con-
firmed a strong association in men of the cholesterol content 
in small dense LDL (LDLc <255Ε) with the risk for ischemic 
heart disease compared with the relationship of large LDL 
(>260 Ε) to the risk that was weak. This strong association 
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was independent of factors such as HDL-C, triglyceride and 
apolipoprotein B. In an analysis of subjects with the metabolic 
syndrome in the Framingham Heart Study21, small LDL parti-
cle level was increasing with an increasing number of metabolic 
syndrome traits and those with the syndrome had higher risk 
for cardiac heart disease. Other studies have confirmed that 
subjects with increased small, dense LDL levels exhibit also 
increased VLDL, small, dense HDL and low total HDL lev-
els22. It seems that central obesity leads to an increase content 
of fat in the liver with subsequent increased production and 
secretion of VLDL. Insulin resistance disturbs the correct 
regulation of VLDL production and low adiponectin is associ-
ated with low VLDL clearance rate. Increased VLDL levels 
is the key feature of a dyslipidemic syndrome which initiates a 
sequence of events that generates the atherogenic small, dense 
LDL and HDL particles and it is common in diabetes, in the 
metabolic syndrome, in familial combined hyperlipidaemia, in 
preeclampsia, etc22,23. However small, dense LDL levels failed 
to predict the onset of frank diabetes in prediabetic subjects 
whereas VLDL and small HDL concentration appeared to be 
related to future onset of diabetes24. 
The role of small, dense LDL cholesterol in the patho-
genesis and progression of the atheromatous plaque has 
recently been elucidated. Small, dense LDL is more easily 
oxidized and is subject to a higher degree of retention in the 
arterial wall. Small, dense LDL also exhibits reduced binding 
capacity to the LDL-receptor, thus is staying longer in the 
circulation and is subject to more structural changes which 
can increase its atherogenic potential. Small, dense LDL pro-
motes endothelial dysfunction, inducing greater production 
of plasminogen activator inhibitor (PAI)-I and thromboxane 
A
2
25. Interventions that would modify small, dense LDL level 
include administration of statins that reduce all LDL subfrac-
tions, administration of fibrates in which case the benefits are 
greater in individuals with a predominance of small, dense 
LDL particles and apparently peroxisome- activated receptor 
γ agonists seem to be able to alter particle size in diabetes, 
metabolic syndrome, and in hypertension without a change in 
plasma VLDL or triglyceride concentration26.
c O N c L U s I O N
Increasing number of studies are supporting the incremen-
tal value of measuring non-LDL and especially apolipopro-
tein-B. Patients already on statins with high apo-B plasma level 
may still have too many small, dense LDL particles which are 
highly atherogenic and may warrant more aggressive approach 
and management maybe in the form of combination of lipid- 
lowering drugs. Current guidelines clearly set LDL-C as the 
primary target of lipid lowering therapy and introduce non-
HDL as a secondary target of therapy in patients with elevated 
triglycerides level (≥200 mg/dl)8. As for the therapeutic strate-
gies, statins remain the mainstay of treatment for increased 
LDL as well as non-HDL cholesterol even as monotherapy. 
When LDL cholesterol is extremely high, a combination of 
drug therapy is advised, e.g. statins and bile acid sequestrant 
in order to reach the therapeutic goal. 
Ezetimibe has complementary action to the statins add-
ing an extra 20% LDL reduction and its clinical significance 
was studied in the ENHANCE trial27 that was published 
earlier this year. The results were disappointing and raised 
much speculation since the study failed to show any benefit 
in the intima media thickness in the carotid arteries from the 
treatment with the combination of simvastatin and ezetimibe 
compared to simvastatin alone. Fibrates are considered for 
monotherapy only when triglycerides are over 500 mg/dl due 
to high risk of acute pancreatitis. However, when triglycerides 
fall below 500 mg/dl, LDL becomes again the primary target 
of therapy and statins are usually combined with a fibrate 
or nicotinic acid. The latter two drugs also increase HDL. 
However, ATP III does not specify a certain goal for HDL in 
patients with decreased levels as in the metabolic syndrome 
and outline the importance of LDL lowering as a primary 
target. Adding a drug such as a fibrate in a patient with low 
HDL after reaching LDL target may be considered in high risk 
populations. Torcertapib, a cholesteryl ester transfer protein 
(CETP) inhibitor was a promising drug that could substantially 
increase HDL cholesterol. However, a phase III trial, the IL-
LUMINATE trial,28 was terminated early because an interim 
analysis showed an increased rate of mortality in patients 
receiving the combination of atorvastatin and torcetrapib 
compared to those receiving atorvastatin alone. 
Finally, it is very important to note that a majority of high 
risk patients even on a statin have very high levels of LDL 
cholesterol according to the ASPIRE2 and EUROASPIRE30 
registries. Therefore, all possible interventions should be 
implemented in patients according to the existing guidelines 
in order to reach the therapeutic targets and consequently 
reduce mortality and risk for cardiovascular events. Further 
large scale prospective clinical trials will clarify the clinical 
circumstances that justify further lipoprotein analysis and 
how to best use the information taken from new indices such 
as non-HDL, apolipoprotein B or small dense LDL particles, 
in the management of our patients. 
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